Skip to main content

Table 5 Model-based Relationship (B) between Medication Class and Driving Outcomes, Adjusted for Covariatesa

From: Medication use and driving patterns in older drivers: preliminary findings from the LongROAD study

 

Speeding

Rapid Deceleration

Right-to-Left Turn Ratio

Medication Class

B

p-value

B

p-value

B

p-value

Antihistamine

−.018

.790

−.010

.779

.016

.016

Anti-infective agents

.059

.424

−.027

.515

−.012

.096

Anti-neoplastic agents

.221

.054

.058

.376

.008

.469

Autonomic

.024

.670

.052

.099

.005

.394

Blood Formation, Coagulation

−.079

.242

.021

.586

−.003

.674

Cardiovascular

−.031

.561

−.055

.068

−.004

.487

CNS agents

.143

.004

.040

.165

.040

.165

Electrolytic

−.078

.105

−.110

<.001

.000

.933

EENT

−.075

.164

.046

.139

.003

.583

Gastrointestinal drugs

.058

.242

.061

.032

.006

.219

Hormones and synthetic substitutes

.054

.252

.060

.024

.003

.562

Local anesthetics

−.002

.993

.133

.350

.001

.966

Skin and mucous membrane agents

−.005

.936

.029

.423

−.005

.454

Smooth Muscle Relaxants

.007

.957

−.020

.779

−.002

.893

Vitamins

−.021

.675

−.034

.228

−.010

.053

  1. aCovariates: total number of medications, miles driven per year, total days driving, sex, age, race/ethnicity, education, urban/rural residence, income, employment, study site